Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients

Carmine Pinto; Maria Angela Bella; Ettore Capoluongo; Paola Carrera; Claudio Clemente; Nicoletta Colombo; Laura Cortesi; Gaetano De Rosa; Francesca Fenizia; Maurizio Genuardi; Stefania Gori; Valentina Guarneri; Antonio Marchetti; Paolo Marchetti; Nicola Normanno; Barbara Pasini; Sandro Pignata; Paolo Radice; Enrico Ricevuto; Antonio Russo; Pierosandro Tagliaferri; Pierfrancesco Tassone; Mauro Truini; Liliana Varesco

doi:10.2217/fon-2016-0189

Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients

Future Oncol. 2016 Sep;12(18):2071-5. doi: 10.2217/fon-2016-0189. Epub 2016 May 31.

Authors

Carmine Pinto¹, Maria Angela Bella², Ettore Capoluongo³, Paola Carrera⁴, Claudio Clemente⁵, Nicoletta Colombo⁶, Laura Cortesi⁷, Gaetano De Rosa⁸, Francesca Fenizia⁹, Maurizio Genuardi¹⁰, Stefania Gori¹¹, Valentina Guarneri¹², Antonio Marchetti¹³, Paolo Marchetti¹⁴, Nicola Normanno¹⁵, Barbara Pasini¹⁶, Sandro Pignata¹⁷, Paolo Radice¹⁸, Enrico Ricevuto¹⁹, Antonio Russo²⁰, Pierosandro Tagliaferri²¹, Pierfrancesco Tassone²², Mauro Truini²³, Liliana Varesco²⁴

Affiliations

¹ Medical Oncology S.Maria Nuova Hospital - IRCCS Reggio Emilia, Italy.
² Medical Oncology Unit, University Hospital of Parma, Italy.
³ Institute of Biochemistry & Clinical Biochemistry, Catholic University of the Sacred Heart, Rome, Italy.
⁴ Unit of Genomics for Diagnosis of Human Pathologies, Division of Genetics & Cell Biology, & Laboratory of Clinical Molecular Biology, IRCCS Ospedale San Raffaele, Milan, Italy.
⁵ Pathology & Cytopathology Unit, Casa di Cura San Pio X & IRCCS Policlinico San Donato, Milano, Italy.
⁶ European Institute of Oncology 'IEO', Milan, Italy.
⁷ Department of Oncology, Hematology & Respiratory Diseases, University Hospital of Modena, Italy.
⁸ Department of Advanced Biomedical Sciences, Pathology Section, University of Naples Federico II, Naples, Italy.
⁹ Pharmacogenomic Laboratory, Centro di Ricerche Oncologiche di Mercogliano (CROM), Istituto Nazionale per lo Studio e la Cura dei Tumori "Fondazione Giovanni Pascale" - IRCCS Naples, Italy.
¹⁰ Institute of Genomic Medicine, 'A Gemelli' School of Medicine, Catholic University of the Sacred Heart, Rome, Italy.
¹¹ Department of Oncology, Ospedale Sacro Cuore Don Calabria, Negrar-Verona, Italy.
¹² Department of Surgery, Oncology & Gastroenterology, University of Padova; Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy.
¹³ Center of Predictive Molecular Medicine, University-Foundation, CeSI Biotech Chieti, Italy.
¹⁴ Clinical & Molecular Medicine Department, Sapienza University, Rome, Italy.
¹⁵ Cell Biology & Biotherapy Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori 'Fondazione Giovanni Pascale' - IRCCS Naples, Italy.
¹⁶ Department of Medical Science, University of Turin, Turin, Italy.
¹⁷ Uro-Gynecological Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori 'Fondazione Giovanni Pascale' - IRCCS Naples, Italy.
¹⁸ Unit of Molecular Bases of Genetic Risk & Genetic Testing, Department of Preventive & Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
¹⁹ Oncology Network ASL1 Abruzzo, Oncology Territorial Care Unit, Division of Medical Oncology, Department of Biotechnological & Applied Clinical Sciences, University of L'Aquila, Italy.
²⁰ Department of Surgical, Oncological & Oral Sciences, Section of Medical Oncology, University of Palermo, Italy.
²¹ Department of Experimental & Clinical Medicine, Magna Graecia University, Salvatore Venuta University Campus, Catanzaro, Italy.
²² Sbarro Institute for Cancer Research & Molecular Medicine, Center for Biotechnology, College of Science & Technology, Temple University, Philadelphia, PA, USA.
²³ Pathological Anatomy Histology & Cytogenetics, Niguarda Cancer Center, Niguarda Ca' Granda Hospital, Milan, Italy.
²⁴ Unit of Hereditary Cancers, IRCCS AOU San Martino - IST, Genoa, Italy.

PMID: 27241581
DOI: 10.2217/fon-2016-0189

No abstract available

Keywords: BRCA1; BRCA2; PARP inhibitors; genetic testing; germline mutations; ovarian cancer; somatic mutations.

Publication types

Review

MeSH terms

Biomarkers, Tumor
Clinical Decision-Making
Disease Management
Female
Genes, BRCA1
Genes, BRCA2*
Genetic Testing* / methods
Genetic Variation
Germ-Line Mutation
Humans
Informed Consent
Mutation
Ovarian Neoplasms / diagnosis*
Ovarian Neoplasms / mortality
Ovarian Neoplasms / therapy*
Prognosis

Substances

Biomarkers, Tumor